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Abstract
Syncope in the general population is a frequent event often leading to hospitalization, but it is 
unclear whether syncope in the general population is an independent risk marker for adver-
se prognosis. In this review, we investigate the current literature and evaluate the prognosis 
and impact of syncope on adverse outcomes including death and recurrences across different  
populations with focus on the general population. In wide terms, a syncopal event is related to  
a higher risk of subsequent falls and injury and cardiac syncope is particularly associated with 
increased mortality as compared to non-cardiac syncope. The overall prognosis in the general 
population is by large determined by the underlying presence and severity of a given cardiac 
disease, but a given underlying cardiac disease can very well be unknown at the time of first 
syncope so that syncope is the presenting symptom resulting in an independent risk increase. 
Moreover, syncope is a significant risk predictor of a recurrence across populations. It is im-
portant to recognize several risk factors associated with adverse outcome in order to safely 
navigate in a population where most patients with syncope are healthy and low-risk but where 
a small number of patients have life-threatening conditions. Further research in the general 
population should attempt to categorize which patients with syncope need immediate referral 
and diagnostic testing, and whether this affects the outcome. (Cardiol J 2014; 21, 6: 631–636)
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Introduction
Assessment of risk for serious cardiovascular 
(CV) outcome after syncope is difficult. Confound­
ing is one of the many challenges. Confounding in 
epidemiological studies of syncope particularly 
concerns the fact that, in general, patients with 
syncope are sicker than patients without syncope. 
Even though statistical analysis in studies may 
adjust for this imbalance of known influencing 
factors, other unknown factors may influence the 
results. This apparent issue, in particular, makes it 
difficult to evaluate if syncope per se is a risk factor 
in the general population. In order to further inve-
stigate this enigma, it is helpful to conceptualize 
the available data.
To understand if syncope is a risk predictor 
in various populations it is important first to es-
tablish which outcomes are relevant to consider 
for syncope patients. Among all syncope patients, 
a risk outcome could be traumatic fall-related in-
jury because of a new syncopal episode (recurrent 
631www.cardiologyjournal.org
REVIEW ARTICLE
Cardiology Journal 
2014, Vol. 21, No. 6, 631–636
DOI: 10.5603/CJ.a2014.0073
Copyright © 2014 Via Medica
ISSN 1897–5593
Address for correspondence: Martin H. Ruwald, MD, PhD, Heart Research Follow-up Program, Division of Cardiology,  
University of Rochester Medical Center, 265 Crittenden Boulevard, Rochester, 14642 NY, USA, e-mail: mruwald@hotmail.com
Received: 07.09.2014 Accepted: 23.09.2014
syncope). Other outcomes to comprehend could be 
all-cause death, CV death or sudden cardiac death 
alone. Among younger patients, an outcome of 
interest could be future development of significant 
CV disease (CVD) and among elder patients, an 
outcome could be immediate or future need for 
pacemaker. Physicians must incorporate all one 
of these issues when evaluating a patient with 
syncope even if the episode most likely is a single 
case of vasovagal syncope.
Based on the above premises it is useful to 
look at specific age groups because of the variety 
in prevalence of important comorbidities, use of 
concomitant medications and, perhaps most im-
portantly, the presumptive cause of the syncopal 
episode. Essentially, the question comes down to 
whether syncope in itself is a risk factor for morta-
lity or if it is the underlying heart disease (known 
or unknown) that is the cause of a higher risk.
Cause of syncope according  
to age and clinical setting
The prevalence and causes of syncope differ 
depending on both age and the clinical setting in 
which the patient presents and is investigated. 
Additionally, differences in diagnostic definitions, 
administrative care pathways, and population de-
mographics make comparison between different 
studies challenging [1–6]. Reflex (vasovagal) syn-
cope, defined as a transient loss of consciousness 
caused by systemic arterial hypotension resulting 
from reflex vasodilatation or bradycardia or both, 
is the most frequent observed cause of syncope in 
all age groups. Syncope caused by various CVD is 
the second most observed cause. The prevalence 
of CVD however, varies significantly with clinical 
setting exhibiting higher frequencies among the 
elderly and in the emergency and cardiology set-
tings. However, at least 2 issues pertain to these 
observations. First, the diagnostic accuracy of 
syncope testing and by basing specific diagnosis on 
the history (i.e. assigning the diagnosis based on 
typical vasovagal symptoms) differ between physi-
cians, setting and patients. Second, the diagnosis of 
cardiac syncope or syncope related to CVD depends 
on the work-up, which may be inaccurate and differ 
by setting, physicians and patient preferences. In 
contrast to the relatively high frequency of con-
comitant CVD in the elderly seen in the hospital 
setting, cardiac origin of syncope is quite rare in 
the general population and in the young. This not-
withstanding, overuse and a “shot-gun” approach 
of diagnostic procedures to diagnose (or fear of 
missing) a potential very rare and life-threatening 
channelopathy are common [7, 8].
Orthostatic hypotension is very frequent 
among old patients and a rare cause of syncope in 
the young. The rate of unexplained syncope simi-
larly reflects the clinical setting with decreasing 
rate in specialized syncope clinics and cardiology 
settings. In all settings, the incidence of syncope 
increases with age with bimodal peaks in adole-
scence and in old age. In short, the elderly accounts 
for the vast majority of patients represented in the 
general population, general practice, and Emergen-
cy Department (ED) and Cardiology Departments. 
Moreover, the temporal relationship may be an 
issue. If syncope occurred 20 years before death, 
one wonders if the 2 events are really related. 
These aspects are important to keep in mind when 
trying to answer the question whether syncope is 
a risk factor in the general population.
Prognosis in the general population
The Framingham Heart Study [9] (n = 7,814) 
evaluated the incidence and prognosis among the 
participants in this study of the general population. 
Syncope occurred in 822 patients during a follow-up 
of 17 years (6.2 per 1,000 person-years). This low 
incidence is in sharp contrast with later studies 
reporting a life-time cumulative incidence of 35% 
[10], which can be explained by the fact that in the 
Framingham study, only subjects who experienced 
syncope during the study were asked if they had 
also experienced syncope at a younger age.
In the Framingham study, a presumed vasova-
gal cause was observed in 21%, a cardiac cause in 
9%, while for 37% the cause of syncope remained 
unknown or unexplained. In adjusted multivariate 
analysis, the all­cause mortality was significantly 
higher in patients with cardiac cause of syncope 
when compared to patients with syncope from 
other causes. In secondary analyses, the authors 
further stratified by presence of CVD and reported 
that cardiac syncope with or without known pre-
sence of CVD were associated with increased mor-
tality risk (hazard ratio [HR] 2.01, 95% confidence 
interval [CI] 1.48–2.73). The study also provided 
reassurance that vasovagal syncope with or without 
presence of known CVD was not associated with 
excess mortality (HR 1.08, 95% CI 0.88–1.34).
One key point was that it is important to re-
cognize that cardiac syncope can be a precursor of 
sudden death with a relative high mortality rate 
independent of the presence of known CVD (in 
some cases), but the study had major limitations 
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concerning the diagnostic classification of syncope 
and collected clinical information. In particular, it 
can be noted that the patients generally had no 
comorbidities but if they did the cause for syn-
cope even if it were vasovagal would potentially 
be ascribed to something else. The diagnostic 
procedures were not noted or systematic. Further 
the presence of syncope with CVD is not the same 
as syncope caused by CVD resulting in possible 
mis-adjudication of syncope in the study.
Prognosis in other populations
Earlier (pre­implantable cardioverter­defibril-
lator era) reports by Kapoor et al. [11, 12] from 
hospitalized patients in the 1990’s established 
that cardiac syncope had higher mortality than 
non-cardiac syncope. One study [11] (n = 433) 
found 5­year mortality to be significantly higher 
(51%) in patients with cardiac cause of syncope 
when compared to patients with non-cardiac or 
unknown cause of syncope (24%). The incidence 
of sudden cardiac death was significantly higher 
(33%) in patients with cardiac cause of syncope 
when compared to non-cardiac (5%) or unknown 
cause of syncope (9%). However, the outcome after 
cardiac syncope was determined by the underlying 
heart disease rather than syncope itself, because 
underlying heart diseases were risk factors for 
mortality, regardless of whether the patient had 
syncope or not. This observation is in contrast to 
the studies described below.
Vanbrabant et al. [13] compared the outcome 
of syncope patients (n = 2,785) from primary care 
and matched these with patients without syncope 
(n = 13,909). A serious outcome was defined as 
the occurrence of a new CV event or serious injury 
and was reported in 12% of the syncope patients 
within 1 year. The predictors for serious outcome 
were increasing age, presence of CV comorbidity 
and CV risk factors. In adjusted analysis, they 
show ed that syncope was an independent predictor 
for serious outcome (HR 3.99, 95% CI 3.44–4.63), 
but this study did not incorporate the cause of 
syncope in the analysis.
Additionally, several studies have investiga-
ted the prognosis after syncope in ED [14–21]. 
In general, in ED there is a shift towards more 
serious cardiac causes and, in older subjects, to-
wards more orthostatic hypotension compared to 
the general population. Reflex syncope, however, 
remains the most prevalent cause of syncope. 
These studies identified important predictors of 
adverse outcomes and short-term mortality among 
syncope patients. In the Evaluation of Guidelines, 
in Syncope Study (EGSYS) [19] the 1-year morta-
lity rate of syncope in general was 5% and in the 
second EGSYS study [22] the 2-year mortality rate 
was 9%. In the Osservatorio Epidemiologico sulla 
Sincope nel Lazio Study (OESIL) [15], the 1-year 
mortality was 12%, in the Short-term Prognosis of 
Syncope (STePS) Study [21] 6%, in the Risk strati-
fication of Syncope in the Emergency Department 
(ROSE) Study [23] 7%, in a study by Martin et al. 
[20] 15% and 7% in a recent retrospective registry 
study from EDs [24]. These studies represent 
a broad mix of all-cause syncope patients and the 
characteristics and mortality rates likely reflect the 
patients seen in most ED in the Western world. 
Additionally, these studies developed several 
risk scores and classifications, but unfortunately, 
with unsuccessful implementation and validation. 
A meta-analysis summarized the most important 
risk factors associated with adverse outcome to 
be palpitations preceding syncope, syncope during 
effort, history of heart failure or ischemic heart 
disease and clinical and laboratory evidence of 
bleeding [25]. Similar to the general population, in 
the ED, cardiac syncope was also associated with 
both higher short- and long-term occurrences of 
adverse events [26].
Finally, in hospitalized syncope patients, 
a large registry-based study [27] (n = 37,017) 
suggested that syncope in patients without any 
prior history of comorbidities may constitute an 
increased risk of CV morbidity and mortality when 
compared to a general background population. 
Multivariable Cox regression analysis showed 
significantly higher all-cause mortality and CV hos - 
pitalizations across age groups when compared to 
the control subjects without syncope. Importantly, 
the study did not evaluate the specific temporal 
relationship from syncope to death and did not 
have information on electrocardiography (ECG), 
lab tests or history and it is reasonable to question 
whether these patients truly were healthy becau-
se they did not have a prior hospitalization. The 
findings in this study emphasize the importance 
of careful, timely and thorough initial evaluation 
of all patients with syncope and the need for dili-
gent risk stratification is warranted. However, 
no data has yet proven that risk stratification can 
alter outcomes.
Syncope work-up
A history should be obtained and physical 
examination and ECG should be performed in all 
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patients, with the initial goal of risk stratification 
and exclusion of an acute illness, such as myocar-
dial infarction or pulmonary embolism, as the 
cause of syncope. The precise cause of syncope 
is identified during the initial evaluation in fewer 
than half of the patients [28], but the presence or 
absence of heart disease offers important informa-
tion about the need for further evaluation and risk 
stratification [29].
Among patients with various forms of es-
tablished heart disease the overall prognosis and 
mechanism of patients with syncope depends on 
the severity and type of underlying heart disease. 
For most heart diseases, syncope is an independent 
marker of adverse prognosis and sudden death 
compared to patients without syncope often re-
presenting a malignant brady- or tachyarrhythmia. 
Underlying heart disease or not, cardiac syncope 
is associated with adverse prognosis across all 
studied populations. The mechanism of syncope re- 
flects the underlying heart disease with increasing 
likelihood of arrhythmic syncope in more severe 
heart diseases and increasing likelihood of reflex 
syncope in less severe heart disease. In selected 
heart diseases, syncope is further associated with 
increased mortality independently of the causal 
mechanism [30–33]. Even in the absence of 
a firm diagnosis of cardiac syncope, the presence 
of structural cardiac abnormalities or evidence of 
a primary electrical disorder is associated with 
a poor prognosis.
In contrast, a structurally normal heart with 
a normal ECG is associated with a benign etiology 
for syncope and a favorable prognosis but such 
a statement needs to be confirmed in larger data. 
Echocardiography and ECG were not considered 
in the Danish study on the risk of mortality in 
presumably healthy people with syncope where 
syncope was shown to be an independent predictor 
of death [27]. The absolute risk of death after syn-
cope in this study was very low. High-risk cases of 
syncope have either structural or electrical cardiac 
anomalies. As these anomalies may be subtle, par-
ticularly in the general population, it is essential 
to identify potentially lethal causes of syncope 
by ECG as shown in Table 1. Conditions that are 
quite common in the average general population 
and often have syncope as a presenting symptom 
or as an associated symptom are shown in Table 2. 
Table 3 shows the risk factors that are suggestive 
of cardiac syncope or adverse outcome requiring 
prompt further investigations.
Risk of recurrence
The risk of recurrent syncope remains an 
important issue when evaluating syncope as 
a risk predictor. It is well known that the number 
of previous syncopal episodes denotes the like-
lihood of another syncopal episode. In the general 
population, recurrent syncope occurs in approxi-
mately one third of the patients [8] and, although 
probably benign in origin, even vasovagal episodes 
are expected to result in increased traumatic fall-
-related injuries, work-related injuries, and motor 
vehicle accidents [34–36]. Increased susceptibility 
to syncope with advancing age is caused by age-
-related declining physiological regulation of heart 
Table 1. Specific electrocardiography (ECG)  
features.
Significant Q-waves
ECG left ventricular hypertrophy
Pre-excitation — delta waves
ST elevation in the anterior precordial leads  
(Brugada pattern)
T-wave inversion in anterior precordial leads  
(ARVC pattern)
Short QT interval
Long QT interval
Bradyarrhythmias
Persistent sinus bradycardia less than 40 bpm
Sinus pauses 3 s or more
Mobitz II atrioventricular block
Complete heart block or alternating  
bundle branch block
Tachyarrhythmias
Ventricular tachycardia or ventricular fibrillation
ARVC — arrhythmogenic right ventricular cardiomyopathy
Table 2. Frequent cardiac conditions in the general 
population that often cause syncope.
Category Specific condition
Valvular heart disease Aortic stenosis
Coronary artery disease 
and thrombosis
Acute ischemia or  
myocardial infarction 
Pulmonary embolism
Cardiomyopathy Ischemic heart failure
Non ischemic heart failure
Cardiac conduction 
disease
Sinus node dysfunction
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rate, blood pressure and in the cerebral blood flow. 
The risk of recurrence, particularly among the 
elderly, is additionally modified and increased by 
the number of CV drugs taken with orthostatic 
hypotension as side effect as well as influence of 
several comorbidities.
Recent data [37] from a large registry of hospi-
talized syncope patients (n = 70,819) confirmed that 
a recurrence of syncope requiring hospital contact 
was associated with more than a 3-fold increase 
in 1-year all-cause mortality and almost a 4-fold 
increase in 30-day CV death. Recurrent syncope 
was independently associated with increased risk 
of death signifying that recurrent syncope, con-
comitant CVD present or not, is a risk factor for 
mortality. Future studies from these databases will 
elucidate the incidence and influence of fall­related 
injuries and fractures as well as risk of motor vehicle 
accidents in this population. The Irish Longitudinal 
on Ageing (TILDA) [38] study is a population-based 
(n = 8,163) project of adults over the age of 50 and 
was described in a recent review. Preliminary data 
from the study suggested that those with syncope 
were more likely to be female, have CVD or cerebro-
vascular disease, and be on CV and/or psychotropic 
medications. A total of 38% of patients had further 
experienced one or more falls in past year compared 
to 18% of those without syncope, signifying the 
overlap of symptoms and classification between falls 
and syncope — an issue that most likely underesti-
mate the true incidence of syncopal attacks. Among 
the elderly, orthostatic intolerance syndromes 
comprise a heterogeneous group where the history, 
pathophysiology and epidemiology are diverse. In 
a recent review, orthostatic intolerance was perceived 
as a ‘hidden danger’ leading to syncopal attacks, 
increasing mortality and complicating the treatment 
of concomitant diseases such as hypertension and 
heart failure [39].
Finally, the risk for a syncope patient who 
drives can be measured as either the risk of recur-
rent syncope, or by the risk of recurrence while 
driving, or by the risk of recurrence while driving 
and with a related accident. This risk can then be 
compared with accident rate and injury rates of 
drivers currently allowed to drive. To date, it is 
unclear if syncope patients have increased risk 
of motor vehicle accidents and consequently it 
is unknown if the rate of motor vehicle accidents 
among syncope patients exceed the rate set as 
“tolerable” by society [40].
Conclusions
In conclusion, whether syncope is an indepen-
dent risk marker in the general population really 
relates to the outcome in question. Syncope in ge-
neral is related to a higher risk of subsequent falls 
and injury, and cardiac syncope is associated with 
increased mortality as compared to non-cardiac 
syncope. The overall prognosis in the general 
population, however, is by large determined by 
the underlying presence and severity of a given 
cardiac disease. A hospitalization for syncope even 
among healthy individuals is, however associated 
with increased mortality, perhaps due to unrecog-
nized CVD. Moreover, there seems no doubt that 
syncope in general is a risk predictor of a recur-
rence (although this may differ by age, gender, 
and presumed cause of syncope). In the general 
population, it is important to recognize several 
risk factors associated with adverse outcome in 
order to safely navigate in a population where 
most patients with syncope are healthy and low-
-risk but where a small number of patients have 
life-threatening conditions. Further research in 
the general population should attempt to categori-
ze which patients with syncope need immediate 
referral and diagnostic testing and whether this 
affects the outcome.
Conflict of interest: None declared
Table 3. Risk factors suggestive of cardiac  
syncope or adverse outcome. Adapted from [8].
History
Palpitations at time of syncope
Shortness of breath
Syncope during exertion or in supine position
A family history of sudden cardiac death or  
premature death
Significant heart disease
Prior myocardial infarction or other severe  
coronary artery disease
Cardiomyopathy
Other significant structural heart disease
Comorbidities associated with syncope and  
adverse outcomes
Renal failure
Severe anemia
Electrolyte disturbances
Other suggested features of adverse outcome  
in syncope
Age > 65
High B-type natriuretic peptide levels
Low blood pressure at presentation
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